Neurocrine Biosciences Reportedly Nearing $2.5B+ Acquisition of Soleno Therapeutics
Summary
Neurocrine Biosciences is reportedly nearing a deal to acquire rare genetics drugmaker Soleno Therapeutics for more than $2.5 billion, according to the Financial Times. This potential acquisition represents a highly material strategic move for Neurocrine, given the deal value exceeds $2.5 billion against its $13.2 billion market capitalization. The acquisition would significantly expand Neurocrine's pipeline and market presence in rare genetics. For Soleno Therapeutics, this would likely translate into a substantial premium for its shareholders. Investors will be watching for official confirmation of the deal, the precise financial terms, and the market's reaction to the strategic rationale and potential financing structure.
At the time of this announcement, NBIX was trading at $131.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $84.23 to $160.18. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Reuters.